CM
BOLD

Caption Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Caption Management’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-20,000
Closed -$757K – 982
2019
Q2 		$757K Buy
+20,000
New +$768K 0.04% 418

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Caption Management's BOLD Position: Q3 2019 in Review

Caption Management sold out of Audentes Therapeutics, Inc (BOLD) in Q3 2019, closing a stake of 20,000 shares — an estimated $757K sold.

Caption Management first reported a position in BOLD in Q2 2019 and held it in 1 quarter. The position peaked at $757K in Q2 2019. 149 funds tracked by Wall St. Rank hold BOLD as of Q3 2019.

  • Caption Management reported no remaining Audentes Therapeutics, Inc position as of Q3 2019 after selling out during the quarter.
  • Caption Management sold 20,000 Audentes Therapeutics, Inc shares in Q3 2019, an estimated $757K.
  • Caption Management first reported a position in Audentes Therapeutics, Inc in Q2 2019 and held it in 1 quarter.
  • Caption Management's Audentes Therapeutics, Inc position peaked at $757K in Q2 2019.
  • 149 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q3 2019.

Based on Caption Management's 13F filing for Q3 2019, filed 14 Nov 2019.